Biomarkers of Esophageal Adenocarcinoma and Barrett's Esophagus

Cancer Research

Volumn 64, Issue 5, 2004, Pages 1561-1569

  McManus, Damian T ^a,b   Olaru, Andreea ^c   Meltzer, Stephen J ^c  

^a ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; KI 67 ANTIGEN; PROTEIN P53; TUMOR MARKER; VILLIN; CYCLIN D1; DNA;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CANCER RISK; DISEASE MARKER; ESOPHAGUS CARCINOMA; HETEROZYGOSITY LOSS; HUMAN; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; ESOPHAGUS TUMOR;

ADENOCARCINOMA; BARRETT ESOPHAGUS; BIOLOGICAL MARKERS; CYCLIN D1; DNA, NEOPLASM; ESOPHAGEAL NEOPLASMS; HUMANS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 1642365603     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2438     Document Type: Review

References (131)

1. Blot, W. J., and McLaughlin, J. K. The changing epidemiology of esophageal cancer. Semin. Oncol., 26: 2-8, 1999.
2. Powell, J., and McConkey, C. C. The rising trend in oesophageal adenocarcinoma and gastric cardia. Eur. J. Cancer Prev., 1: 265-269, 1992.
3. Conio, M., Cameron, A. J., Romero, Y., Branch, C. D., Schleck, C. D., Burgart, L. J., Zinsmeister, A. R., Melton, L. J., III, and Locke, G. R., III. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut, 48: 304-309, 2001.
4. Wallace, M. B., Nietert, P. J., Earle, C., Krasna, M. J., Hawes, R. H., Hoffman, B. J., and Reed, C. E. An analysis of multiple staging management strategies for carcinoma of the esophagus: computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/laparoscopy. Ann. Thorac. Surg., 74: 1026-1032, 2002.
5. Fink, U., Stein, H. J., and Siewert, J. R. [Multimodal therapy of tumors of the upper gastrointestinal tract]. Chirurg, 69: 349-359, 1998.
6. Dulai, G. S., Guha, S., Kahn, K. L., Gombein, J., and Weinstein, W. M. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology, 122: 26-33, 2002.
7. Corley, D. A., Levin, T. R., Habel, L. A., Weiss, N. S., and Buffler, P. A. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology, 122: 633-640, 2002.
8. Vaughan, T. L., Davis, S., Kristal, A., and Thomas, D. B. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol. Biomark. Prev., 4: 85-92, 1995.
9. Gammon, M. D., Schoenberg, J. B., Ahsan, H., Risch, H. A., Vaughan, T. L., Chow, W. H., Rotterdam, H., West, A. B., Dubrow, R., Stanford, J. L., Mayne, S. T., Farrow, D. C., Niwa, S., Blot, W. J., and Fraumeni, I. F., Jr. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J. Natl. Cancer Inst. (Bethesda), 89: 1277-1284, 1997.
10. Chow, W. H., Blot, W. J., Vaughan, T. L., Risch, H. A., Gammon, M. D., Stanford, J. L., Dubrow, R., Schoenberg, J. B., Mayne, S. T., Farrow, D. C., Ahsan, H., West, A. B., Rotterdam, H., Niwa, S., and Fraumeni, J. F., Jr. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J. Natl. Cancer Inst. (Bethesda), 90: 150-155, 1998.
11. Lagergren, J., Bergstrom, R., and Nyren, O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann. Intern. Med., 130: 883-890, 1999.
12. Lagergren, J., Bergstrom, R., Lindgren, A., and Nyren, O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N. Engl. J. Med., 340: 825-831, 1999.
13. Vaezi, M. F., and Richter, J. E. Importance of duodeno-gastro-esophageal reflux in the medical outpatient practice. Hepatogastroenterology, 46: 40-47, 1999.
14. Kauer, W. K., Burdiles, P., Ireland, A. P., Clark, G. W., Peters, J. H., Bremner, C. G., and DeMeester, T. R. Does duodenal juice reflux into the esophagus of patients with complicated GERD? Evaluation of a fiberoptic sensor for bilirubin. Am. J. Surg., 169: 98-103, 1995.
15. Katzka, D. A., Reynolds, J. C., Saul, S. H., Plotkin, A., Lang, C. A., Ouyang, A., Jimenez, S., and Cohen, S. Barrett's metaplasia and adenocarcinoma of the esophagus in scleroderma. Am. J. Med., 82: 46-52, 1987.
16. Boulton-Jones, J. R., and Logan, R. P. An inverse relation between cagA-positive strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Helicobacter., 4: 281-283, 1999.
17. Farrow, D. C., Vaughan, T. L., Hansten, P. D., Stanford, J. L., Risch, H. A., Gammon, M. D., Chow, W. H., Dubrow, R., Ahsan, H., Mayne, S. T., Schoenberg, J. B., West, A. B., Rotterdam, H., Fraumeni, J. F., Jr., and Blot, W. J. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol. Biomark. Prev., 7: 97-102, 1998.
18. Romero, Y., Cameron, A. J., Locke, G. R., III, Schaid, D. J., Slezak, J. M., Branch, C. D., and Melton, L. J., III. Familial aggregation of gastroesophageal reflux in patients with Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology, 113: 1449-1456, 1997.
19. Chak, A., Lee, T., Kinnard, M. F., Brock, W., Faulx, A., Willis, J., Cooper, G. S., Sivak, M. V., Jr., and Goddard, K. A. Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults. Gut, 51: 323-328, 2002.
20. Eng, C., Spechler, S. J., Ruben, R., and Li, F. P. Familial Barrett esophagus and adenocarcinoma of the gastroesophageal junction. Cancer Epidemiol. Biomark. Prev., 2: 397-399, 1993.
21. El-Omar, E. M., Rabkin, C. S., Gammon, M. D., Vaughan, T. L., Risch, H. A., Schoenberg, J. B., Stanford, J. L., Mayne, S. T., Goedert, J., Blot, W. J., Fraumeni, J. F., Jr., and Chow, W. H. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology, 124: 1193-1201, 2003.
22. Jankowski, J. A., Perry, I., and Harrison, R. F. Gastro-oesophageal cancer: death at the junction. Br. Med. J., 321: 463-464, 2000.
23. Cameron, A. J., Ott, B. J., and Payne, W. S. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N. Engl. J. Med., 313: 857-859, 1985.
24. Spechler, S. J., Robbins, A. H., Rubins, H. B., Vincent, M. E., Heeren, T., Doos, W. G., Colton, T., and Schimmel, E. M. Adenocarcinoma and Barrett's esophagus. An overrated risk? Gastroenterology, 87: 927-933, 1984.
25. Shaheen, N. J., Crosby, M. A., Bozymski, E. M., and Sandler, R. S. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology, 119: 333-338, 2000.
26. Bani-Hani, K., Sue-Ling, H., Johnston, D., Axon, A. T., and Martin, I. G. Barrett's oesophagus: results from a 13-year surveillance programme. Eur. J. Gastroenterol. Hepatol., 12: 649-654, 2000.
27. Avidan, B., Sonnenberg, A., Schnell, T. G., Chejfec, G., Metz, A., and Sontag, S. J. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am. J. Gastroenterol., 97: 1930-1936, 2002.
28. Sampliner, R. E. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am. J. Gastroenterol., 97: 1888-1895, 2002.
29. Coad, R., and Shepherd, N. Barrett's oesophagus: definition, diagnosis and pathogenesis. Curr. Diagn. Pathol., 9: 218-227, 2003.
30. Streitz, J. M., Jr., Andrews, C. W., Jr., and Ellis, F. H., Jr. Endoscopic surveillance of Barrett's esophagus. Does it help? J. Thorac. Cardiovasc. Surg., 105: 383-387, 1993.
31. Streitz, J. M., Jr., Ellis, F. H., Jr., Tilden, R. L., and Erickson, R. V. Endoscopic surveillance of Barrett's esophagus: a cost-effectiveness comparison with mammographic surveillance for breast cancer. Am. J. Gastroenterol., 93: 911-915, 1998.
32. Montgomery, E., Goldblum, J. R., Greenson, J. K., Haber, M. M., Lamps, L. W., Lauwers, G. Y., Lazenby, A. J., Lewin, D. N., Robert, M. E., Washington, K., Zahurak, M. L., and Hart, J. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum. Pathol., 32: 379-388, 2001.
33. Weston, A. P., Sharma, P., Topalovski, M., Richards, R., Cherian, R., and Dixon, A. Long-term follow-up of Barrett's high-grade dysplasia. Am. J. Gastroenterol., 95: 1888-1893, 2000.
34. Schnell, T. G., Sontag, S. J., Chejfec, G., Aranha, G., Metz, A., O'Connell, S., Seidel, U. J., and Sonnenberg, A. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology, 120: 1607-1619, 2001.
35. Reid, B. J., Levine, D. S., Longton, G., Blount, P. L., and Rabinovitch, P. S. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am. J. Gastroenterol., 95: 1669-1676, 2000.
36. Buttar, N. S., Wang, K. K., Sebo, T. J., Riehle, D. M., Krishnadath, K. K., Lutzke, L. S., Anderson, M. A., Petterson, T. M., and Burgart, L. J. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology, 120: 1630-1639, 2001.
37. Alikhan, M., Rex, D., Khan, A., Rahmani, E., Cummings, O., and Ulbright, T. M. Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointest. Endosc., 50: 23-26, 1999.
38. Al Kasspooles, M. F., Hill, H. C., Nava, H. R., Smith, J. L., Douglass, H. O., and Gibbs, J. F. High-grade dysplasia within Barrett's esophagus: controversies regarding clinical opinions and approaches. Ann. Surg. Oncol., 9: 222-227, 2002.
39. Goldblum, J. R., and Lauwers, G. Y. Dysplasia arising in Barrett's esophagus: diagnostic pitfalls and natural history. Semin. Diagn. Pathol., 19: 12-19, 2002.
40. Collard, J. M. High-grade dysplasia in Barrett's esophagus. The case for esophagectomy. Chest Surg. Clin. N. Am., 12: 77-92, 2002.
41. Levine, D. S., Haggitt, R. C., Blount, P. L., Rabinovitch, P. S., Rusch, V. W., and Reid, B. J. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology, 105: 40-50, 1993.
42. Sampliner, R. E. Ablative therapies for the columnar-lined esophagus. Gastroenterol. Clin. North Am., 26: 685-694, 1997.
43. Pacifico, R. J., and Wang, K. K. Nonsurgical management of Barrett's esophagus with high-grade dysplasia. Surg. Oncol. Clin. N. Am., 11: 321-336, 2002.
44. Skacel, M., Petras, R. E., Gramlich, T. L., Sigel, J. E., Richter, J. E., and Goldblum, J. R. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am. J. Gastroenterol., 95: 3383-3387, 2000.
45. van Sandick, J. W., Baak, J. P., van Lanschot, J. J., Polkowski, W., ten Kate, F. J., Obertop, H., and Offerhaus, G. J. Computerized quantitative pathology for the grading of dysplasia in surveillance biopsies of Barrett's oesophagus. J. Pathol., 190: 177-183, 2000.
46. Jankowski, J. A., Wright, N. A., Meltzer, S. J., Triadafilopoulos, G., Geboes, K., Casson, A. G., Kerr, D., and Young, L. S. Molecular evolution of the metaplasia-dysplasiaadenocarcinoma sequence in the esophagus. Am. J. Pathol., 154: 965-973, 1999.
47. Glickman, J. N., Chen, Y. Y., Wang, H. H., Antonioli, D. A., and Odze, R. D. Phenotypic characteristics of a distinctive multilayered epithelium suggests that it is a precursor in the development of Barrett's esophagus. Am. J. Surg. Pathol., 25: 569-578, 2001.
48. Reid, B. J., Weinstein, W. M., Lewin, K. J., Haggitt, R. C., VanDeventer, G., DenBesten, L., and Rubin, C. E. Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions. Gastroenterology, 94: 81-90, 1988.
49. Raskind, W. H., Norwood, T., Levine, D. S., Haggitt, R. C., Rabinovitch, P. S., and Reid, B. J. Persistent clonal areas and clonal expansion in Barrett's esophagus. Cancer Res., 52: 2946-2950, 1992.
50. Barrett, M. T., Sanchez, C. A., Prevo, L. J., Wong, D. J., Galipeau, P. C., Paulson, T. G., Rabinovitch, P. S., and Reid, B. J. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat. Genet., 22: 106-109, 1999.
51. Ransford, R. A., and Jankowski, J. A. Genetic versus environmental interactions in the oesophagitis-metaplasia-dysplasia-adenocarcinoma sequence (MCS) of Barrett's oesophagus. Acta Gastroenterol. Belg., 63: 18-21, 2000.
52. Persons, D. L., Croughan, W. S., Borelli, K. A., and Cherian, R. Interphase cytogenetics of esophageal adenocarcinoma and precursor lesions. Cancer Genet. Cytogenet., 106: 11-17, 1998.
53. Beuzen, F., Dubois, S., and Flejou, J. F. Chromosomal numerical aberrations are frequent in oesophageal and gastric adenocarcinomas: a study using in-situ hybridization. Histopathology, 37: 241-249, 2000.
54. Reid, B. J., Haggitt, R. C., Rubin, C. E., and Rabinovitch, P. S. Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology, 93: 1-11, 1987.
55. Reid, B. J., Blount, P. L., Rubin, C. E., Levine, D. S., Haggitt, R. C., and Rabinovitch, P. S. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology, 102: 1212-1219, 1992.
56. Neshat, K., Sanchez, C. A., Galipeau, P. C., Blount, P. L., Levine, D. S., Joslyn, G., and Reid, B. J. p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology, 106: 1589-1595, 1994.
57. Blount, P. L., Galipeau, P. C., Sanchez, C. A., Neshat, K., Levine, D. S., Yin, J., Suzuki, H., Abraham, J. M., Meltzer, S. J., and Reid, B. J. 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy. Cancer Res., 54: 2292-2295, 1994.
58. Barrett, M. T., Sanchez, C. A., Galipeau, P. C., Neshat, K., Emond, M., and Reid, B. J. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene, 13: 1867-1873, 1996.
59. Kawakami, K., Brabender, J., Lord, R. V., Groshen, S., Greenwald, B. D., Krasna, M. J., Yin, J., Fleisher, A. S., Abraham, J. M., Beer, D. G., Sidransky, D., Huss, H. T., DeMeester, T. R., Eads, C., Laird, P. W., Ilson, D. H., Kelsen, D. P., Harpole, D., Moore, M. B., Danenberg, K. D., Danenberg, P. V., and Meltzer, S. J. Hyper-methylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J. Natl. Cancer Inst. (Bethesda), 92: 1805-1811, 2000.
60. Meltzer, S. J., Yin, J., Manin, B., Rhyu, M. G., Cottrell, J., Hudson, E., Redd, J. L., Krasna, M. J., Abraham, J. M., and Reid, B. J. Microsatellite instability occurs frequently and in both diploid and aneuploid cell populations of Barrett's-associated esophageal adenocarcinomas. Cancer Res., 54: 3379-3382, 1994.
61. Kulke, M. H., Thakore, K. S., Thomas, G., Wang, H., Loda, M., Eng, C., and Odze, R. D. Microsatellite instability and hMLH1/hMSH2 expression in Barrett esophagus-associated adenocarcinoma. Cancer (Phila.), 91: 1451-1457, 2001.
62. Gleeson, C. M., Sloan, J. M., McGuigan, J. A., Ritchie, A. J., Weber, J. L., and Russell, S. E. Ubiquitous somatic alterations at microsatellite alleles occur infrequently in Barrett's-associated esophageal adenocarcinoma. Cancer Res., 56: 259-263, 1996.
63. Esteller, M., Sparks, A., Toyota, M., Sanchez-Cespedes, M., Capella, G., Peinado, M. A., Gonzalez, S., Tarafa, G., Sidransky, D., Meltzer, S. J., Baylin, S. B., and Herman, J. G. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res., 60: 4366-4371, 2000.
64. Wong, D. J., Barrett, M. T., Stoger, R., Emond, M. J., and Reid, B. J. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Cancer Res., 57: 2619-2622, 1997.
65. Eads, C. A., Lord, R. V., Kurumboor, S. K., Wickramasinghe, K., Skinner, M. L., Long, T. I., Peters, J. H., DeMeester, T. R., Danenberg, K. D., Danenberg, P. V., Laird, P. W., and Skinner, K. A. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res., 60: 5021-5026, 2000.
66. Toyota, M., Ahuja, M., Ohe-Toyota, M., Herman, J. G., Baytin, S. B., and Issa, J. P. CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. USA, 96: 8681-6, 1999.
67. Eads, C. A., Lord, R. V., Wickramasinghe, K., Long, T. I., Kurumboor, S. K., Bernstein. L., Peters, J. H., DeMeester, S. R., DeMeester, T. R., Skinner, K. A., and Laird, P. W. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res., 61: 3410-3418, 2001.
68. Suzuki, H., Zhou, X., Yin, J., Lei, J., Jiang, H. Y., Suzki, Y., et al. Intragenic mutations of CDKN2B and CDKN2A in primary human esophageal cancers. Hum. Mol. Genet., 4: 1883-1887, 1995.
69. Wong, D. J., Paulson, T. G., Prevo, L. J., Galipeau, P. C., Longton, G., Blount, P. L., and Reid, B. J. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res., 61: 8284-8289, 2001.
70. Arber, N., Lightdale, C., Rotterdam, H., Han, K. H., Sgambato, A., Yap, E., Ahsan, H., Finegold, J., Stevens, P. D., Green, P. H., Hibshoosh, H., Neugut, A. I., Holt, P. R., and Weinstein, I. B. Increased expression of the cyclin D1 gene in Barrett's esophagus. Cancer Epidemiol. Biomark. Prev., 5: 457-459, 1996.
71. Gleeson, C. M., Sloan, J. M., McGuigan, J. A., Ritchie, A. I., and Russell, S. E. Base transitions at CpG dinucleotides in the p53 gene are common in esophageal adenocarcinoma. Cancer Res., 55: 3406-3411, 1995.
72. Montesano, R., Hollstein, M., and Hainaut, P. Molecular etiopathogenesis of esophageal cancers. Ann. Ist. Super. Sanita, 32: 73-84, 1996.
73. Whittles, C. E., Biddlestone, L. R., Burton, A., Barr, H., Jankowski, J. A., Warner, P. J., and Shepherd, N. A. Apoptotic and proliferative activity in the neoplastic progression of Barrett's oesophagus: a comparative study. J. Pathol., 187: 535-540, 1999.
74. Lauwers, G. Y., Kandemir, O., Kubilis, P. S., and Scott, G. V. Cellular kinetics in Barrett's epithelium carcinogenic sequence: roles of apoptosis, bcl-2 protein, and cellular proliferation. Mod. Pathol., 10: 1201-1208, 1997.
75. Katada, N., Hinder, R. A., Smyrk, T. C., Hirabayashi, N., Perdikis, G., Lund, R. J., Woodward, T., and Klingler, P. J. Apoptosis is inhibited early in the dysplasia-carcinoma sequence of Barrett esophagus. Arch. Surg., 132: 728-733, 1997.
76. Younes, M., Lechago, J., Ertan, A., Finnie, D., and Younes, A. Decreased expression of Fas (CD95/APO1) associated with goblet cell metaplasia in Barrett's esophagus. Hum. Pathol., 31: 434-438, 2000.
77. Takubo, K., Nakamura, K., Izumiyama, N., Mafune, K., Tanaka, Y., Miyashita, M., Sasajima, K., Kato, M., and Oshimura, M. Telomerase activity in esophageal carcinoma. J. Surg. Oncol., 66: 88-92, 1997.
78. Lord, R. V., Salonga, D., Danenberg, K. D., Peters, J. H., DeMeester, T. R., Park, J. M., Johansson, J., Skinner, K. A., Chandrasoma, P., DeMeester, S. R., Bremner, C. G., Tsai, P. I., and Danenberg, P. V. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J. Gastrointest. Surg., 4: 135-142, 2000.
79. Blount, P. L., Meltzer, S. J., Yin, J., Huang, Y., Krasna, M. J., and Reid, B. J. Clonal ordering of 17p and 5q allelic losses in Barrett dysplasia and adenocarcinoma. Proc. Natl. Acad. Sci. USA, 90: 3221-3225, 1993.
80. Powell, S. M., Papadopoulos, N., Kinzler, K. W., Smotinski, K. N., and Meltzer, S. J. APC gene mutations in the mutation cluster region are rare in esophageat cancers. Gastroenterology 107: 1759-63, 1994.
81. Choi, Y. W., Heath, E. I., Heitmiller, R., Forastiere, A. A., and Wu, T. T. Mutations in β-catenin and APC genes are uncommon in esophageal and esophagogastric junction adenocarcinomas. Mod. Pathol., 13: 1055-1059, 2000.
82. Bian, Y. S., Osterheld, M. C., Bosman, F. T., Fontolliet, C., and Benhattar, J. Nuclear accumulation of β-catenin is a common and early event during neoplastic progression of Barrett esophagus. Am. J. Clin. Pathol., 114: 583-590, 2000.
83. Fein, M., Peters, J. H., Baril, N., McGarvey, M., Chandrasoma, P., Shibata, D., Laird, P. W., and Skinner, K. A. Loss of function of Trp53, but not Apc, leads to the development of esophageal adenocarcinoma in mice with jejunoesophageal reflux. J. Surg. Res., 83: 48-55, 1999.
84. Bailey, T., Biddlestone, L., Shepherd, N., Barr, H., Warner, P., and Jankowski, J. Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation. Am. J. Pathol., 152: 135-144, 1998.
85. Eksteen, J. A., Scott, P. A., Perry, I., and Jankowski, J. A. Inflammation promotes Barrett's metaplasia and cancer: a unique role for TNFα. Eur. J. Cancer Prev., 10: 163-166, 2001.
86. Aloia, T. A., Harpole, D. H., Jr., Reed, C. E., Allegra, C., Moore, M. B., Herndon, J. E., and D'Amico, T. A. Tumor marker expression is predictive of survival in patients with esophageal cancer. Ann. Thorac. Surg., 72: 859-866, 2001.
87. Geddert, H., Zeriouh, M., Wolter, M., Heise, J. W., Gabbert, H. E., and Sarbia, M. Gene amplification and protein overexpression of c-erb-b2 in Barrett carcinoma and its precursor lesions. Am. J. Clin. Pathol., 118: 60-66, 2002.
88. Brien, T. P., Odze, R. D., Sheehan, C. E., McKenna, B. J., and Ross, J. S. HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. Hum. Pathol., 31: 35-39, 2000.
89. Meltzer, S. J., Maue, S. M., Wood, P. K., Resav, J. H., Newkirk, C., Terzokis, J. A., et al. Activation of c-Ki-ras in human gastrointestinal dysplasias determined by direct sequencing of polymerase chain reaction products. Cancer Res., 50: 3627-3630, 1990.
90. Arber, N., Shapira, I., Ratan, J., Stern, B., Hibshoosh, H., Moshkowitz, M., Gammon, M., Fabian, I., and Halpern, Z. Activation of c-K-ras mutations in human gastrointestinal tumors. Gastroenterology, 118: 1045-1050, 2000.
91. Souza, R. F., Shewmake, K., Terada, L. S., and Spechler, S. J. Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus. Gastroenterology, 122: 299-307, 2002.
92. Wilson, K. T., Fu, S., Ramanujam K. S., and Meltzer S. J. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus associated adenocarcionmas. Cancer Res., 58: 2929-2934, 1998.
93. Morris. C. D., Armstrong, G. R., Bigley, G., Green, H., and Attwood, S. E. Cyctooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am. J. Gastroenterol., 96: 990-996, 2001.
94. Wilson, K. T. Angiogenic markers, neovascularization and malignant deformation of Barrett's esophagus. Dis. Esophagus, 15: 16-21, 2002.
95. Couvelard, A., Paraf, F., Gratio, V., Scoazec, J. Y., Henin, D., Degott, C., and Flejou, J. F. Angiogenesis in the neoplastic sequence of Barrett's oesophagus. Correlation with VEGF expression. J. Pathol., 192: 14-18, 2000.
96. Srivastava, S., and Rossi. S. C. Early detection research program at the NCI. Int. J. Cancer, 69: 35-37, 1996.
97. Sullivan Pepe, M., Etzioni, R., Feng, Z., Potter, J. D., Thompson, M. L., Thornquist, M., Winget, M., and Yasui, Y. Phases of biomarker development for early detection of cancer. J. Natl. Cancer Inst. (Bethesda), 93: 1054-1061, 2001.
98. Montgomery, E., Bronner, M. P., Greenson, J. K., Haber, M. M., Hart, J., Lamps, L. W., Lauwers, G. Y., Lazenby, A. J., Lewin, D. N., Robert, M. E., Washington, K., and Goldblum, J. R. Are ulcers a marker for invasive carcinoma in Barrett's esophagus? Data from a diagnostic variability study with clinical follow-up. Am. J. Gastroenterol., 97: 27-31, 2002.
99. Scotiniotis, I. A., Kochman, M. L., Lewis, J. D., Furth, E. E., Rosato, E. F., and Ginsberg, G. G. Accuracy of EUS in the evaluation of Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma. Gastrointest. Endosc., 54: 689-696, 2001.
100. Canto, M. I., Setrakian, S., Willis, J. E., Chak, A., Petras, R. E., and Sivak, M. V. Methylene blue staining of dysplastic and nondysplastic Barrett's esophagus: an in vivo and ex vivo study. Endoscopy, 33: 391-400, 2001.
101. Mayinger, B., Neidhardt, S., Reh, H., Martus, P., and Hahn, E. G. Fluorescence induced with 5-aminolevulinic acid for the endoscopic detection and follow-up of esophageal lesions. Gastrointest. Endosc., 54: 572-578, 2001.
102. Hong, M. K., Laskin, W. B., Herman, B. E., Johnston, M. H., Vargo, J. J., Steinberg, S. M., Allegra, C. J., and Johnston, P. G. Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus. Cancer (Phila.), 75: 423-429, 1995.
103. Younes, M., Lebovitz, R. M., Lechago, L. V., and Lechago, J. p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study. Gastroenterology, 105: 1637-1642, 1993.
104. Geboes, K., and Van Eyken, P. The diagnosis of dysplasia and malignancy in Barrett's oesophagus. Histopathology, 37: 99-107, 2000.
105. Polkowski, W., van Lanschot, J. J., ten Kate, F. J., Baak, J. P., Tytgat, G. N., Obertop, H., Voorn, W. J., and Offerhaus, G. J. The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence. Surg. Oncol., 4: 163-171, 1995.
106. Weston, A. P., Banerjee, S. K., Sharma, P., Tran, T. M., Richards, R., and Cherian, R. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. Am. J. Gastroenterol., 96: 1355-1362, 2001.
107. Younes, M., Ertan, A., Lechago, L. V., Somoano, J. R., and Lechago, J. p53 Protein accumulation is a specific marker of malignant potential in Barrett's metaplasia. Dig. Dis. Sci., 42: 697-701, 1997.
108. Bani-Hani, K., Martin, I. G., Hardie, L. J., Mapstone, N., Briggs, J. A., Forman, D., and Wild, C. P. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. J. Natl. Cancer Inst. (Bethesda). 92: 1316-1321, 2000.
109. Rabinovitch, P. S., Longton, G., Blount, P. L., Levine, D. S., and Reid, B. J. Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am. J. Gastroenterol., 96: 3071-3083, 2001.
110. Reid, B. J., Prevo, L. J., Galipeau, P. C., Sanchez, C. A., Longton, G., Levine, D. S., Blount, P. L., and Rabinovitch, P. S. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am. J. Gastroenterol., 96: 2839-2848, 2001.
111. Huang, Y., Mettzer, S. J., Yin, J., Tong, Y., Chang, E. H., Srivastava, S., McDaniel, T., Boynton, R. F., and Zou, Z. Q. Altered mRNA and unique mutational profiles of p53 and Rb in human esophageal carcinomas. Cancer Res. 53: 1889-94, 1993.
112. Hamelin, R., Flejou, J. F., Muzeau, F., Potet, F., Laurent-Puig, P., Fekete, F., and Thomas, G. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology, 107: 1012-1018, 1994.
113. Prevo, L. J., Sanchez, C. A., Galipeau, P. C., and Reid, B. J. p53-mutant clones and field effects in Barrett's esophagus. Cancer Res., 59: 4784-4787, 1999.
114. Coggi, G., Bosari, S., Roncalli, M., Graziani, D., Bossi, P., Viale, G., Buffa, R., Ferrero, S., Piazza, M., Blandamura, S., Segalin, A., Bonavina, L., and Peracchia, A. p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations. Cancer (Phila.), 79: 425-432, 1997.
115. Hardwick, R. H., Morgan, R. J., Warren, B. F., Lott, M., and Alderson, D. Brush cytology in the diagnosis of neoplasia in Barrett's esophagus. Dis. Esophagus, 10: 233-237, 1997.
116. Tsai, T. T., Bongiorno, P. F., Orringer, M. B., and Beer, D. G. Detection of p53 nuclear protein accumulation in brushings and biopsies of Barrett's esophagus. Cancer Detect. Prev., 21: 326-331, 1997.
117. Regalado, S. P., Nambu, Y., Iannettoni, M. D., Orringer, M. B., and Beer, D. G. Abundant expression of the intestinal protein villin in Barrett's metaplasia and esophageal adenocarcinomas. Mol. Carcinog., 22: 182-189, 1998.
118. MacLennan, A. J., Orringer, M. B., and Beer, D. G. Identification of intestinal-type Barrett's metaplasia by using the intestine-specific protein villin and esophageal brush cytology. Mol. Carcinog., 24: 137-143, 1999.
119. Cawley, H. M., Meltzer, S. J., De Benedetti, V. M., Hollstein, M. C., Muehlbauer, K. R., Liang, L., Bennett, W. P., Souza, R. F., Greenwald, B. D., Cottrell, J., Salabes, A., Bartsch, H., and Trivers, G. E. Anti-p53 antibodies in patients with Barrett's esophagus or esophageal carcinoma can predate cancer diagnosis. Gastroenterology, 115: 19-27, 1998.
120. Barrett, M. T., Yeung, K. Y., Ruzzo, W. L., Hsu, L., Blount, P. L., Sullivan, R., Zarbl, H., Delrow, J., Rabinovitch, P. S., and Reid, B. J. Transcriptional analyses of Barrett's metaplasia and normal upper GI mucosae. Neoplasia., 4: 121-128, 2002.
121. Selaru, F. M., Zou, T., Xu, X., Shustova, V., Yin, J., Mori, Y., et al. Global gene expression profiling in Barrett's esophagus and esophageal cancer: a comparative analysis using cDNA microarrays. Oncogene 21: 475-478, 2002.
122. Xu, Y., Selaru, F. M., Yin, J., Zou, T. T., Shustova, V., Mori, Y., Sato, F., Liu, T. C., Olaru, A., Wang, S., Kimos, M. C., Perry, K., Desai, K., Greenwald, B. D., Krasna, M. J., Shibata, D., Abraham, J. M., and Meltzer, S. J. Artificial neural networks and gene filtering distinguish between global gene expression profiles of Barrett's esophagus and esophageal cancer. Cancer Res., 62: 3493-3497, 2002.
123. Buskens, C. J., Van Rees, B. P., Sivula, A., Reitsma, J. B., Haglund, C., Bosma, P. J., Offerhaus, G. J., van Lanschot, J. J., and Ristimaki, A. Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology, 122: 1800-1807, 2002.
124. Buttar, N. S., Wang, K. K., Leontovich, O., Westcott, J. Y., Pacifico, R. J., Anderson, M. A., Krishnadath, K. K., Lutzke, L. S., and Burgart, L. J. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology, 122: 1101-1112, 2002.
125. Buttar, N. S., Wang, K. K., Anderson, M. A., Dierkhising, R. A., Pacifico, R. J., Krishnadath, K. K., and Lutzke, L. S. The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study. J. Natl. Cancer Inst. (Bethesda), 94: 422-429, 2002.
126. Kaur, B. S., Khamnehei, N., Iravani, M., Namburu, S. S., Lin, O., and Triadafilopoulos, G. Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology, 123: 60-67, 2002.
127. Schatzkin, A., and Gail, M. The promise and peril of surrogate end points in cancer research. Nat. Rev. Cancer, 2: 19-27, 2002.
128. Kelloff, G. J., Sigman, C. C., Johnson, K. M., Boone, C. W., Greenwald, P., Crowell, J. A., Hawk, E. T., and Doody, L. A. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. Cancer Epidemiol. Biomark. Prev., 9: 127-137, 2000.
129. Giardiello, F. M., Yang, V. W., Hylind, L. M., Krush, A. J., Petersen, G. M., Trimbath, J. D., Piantadosi, S., Garrett, E., Geiman, D. E., Hubbard, W., Offerhaus, G. J., and Hamilton, S. R. Primary chemoprevention of familial adenomatous polyposis with sulindac. N. Engl. J. Med., 346: 1054-1059, 2002.
130. Eisen, G. M., Montgomery, E. A., Azumi, N., Hartmann, D. P., Bhargava, P., Lippman, M., and Benjamin, S. B. Qualitative mapping of Barrett's metaplasia: a prerequisite for intervention trials. Gastrointest. Endosc., 50: 814-818, 1999.
131. Bhargava, P., Eisen, G. M., Holterman, D. A., Azumi, N., Hartmann, D. P., Hanfelt, J. J., Benjamin, S. B., Lippman, M. E., and Montgomery, E. A. Endoscopic mapping and surrogate markers for better surveillance in Barrett esophagus. A study of 700 biopsy specimens. Am. J. Clin. Pathol., 114: 552-563, 2000.